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accounting for 21.2% and 16.2% of total AED consumption (DDD 
163.7 and 125.2, respectively). In the same year, oxcarbazepine and 
lamotrigine were the most used new AEDs (10.91% and 10.79% of 
total; DDD 84.1 and 83.2, respectively), while gabapentin and pre-
gabalin exhibited the higher incidence of use. The main indication of 
use was epileptic disorders for older AEDs and neuropathic pain for 
newer AEDs. A high number of patients treated with older AEDs, in 
particular carbamazepine, phenobarbital, and valproic acid, received 
coprescription at clinically relevant interaction risk. Among newer 
AEDs, lamotrigine showed a high annual rate of possible interaction.
Conclusion: Significant differences were shown in the prescribing 
pattern of newer and older medications: older AEDs were mainly 
used in the treatment of epileptic disorders, while newer compounds 
were also preferred for conditions other than epilepsy, in particular 
neuropathic pain. The fall in the use of newer AEDs during 2007 
agreed with revised reimbursement criteria for gabapentin and pre-
gabalin. The coprescription should be evaluated with caution and 
avoided if possible. Drugs at risk of interactions should be replaced 
with others having same indication of use.
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Introduction: Drug–drug interactions (DDIs) may have severe and 
life-threatening health consequences. To identify DDIs, a cloud-based 
surveillance has been implemented in a network of 12 pharmacies, 
1 general hospital, and 24 general physicians of the ASS2 Health 
District, North East Italy.
Patients (or Materials) and Methods: DDIs were identified through 
a fully automated, closed loop system that records and updates, by 
specifically designed software interfaces loaded on Information and 
Communication Technology (ICT) programs of the network, all the 
drugs taken during therapy cycle/s. Each patient, agreeing to partici-
pate, was linked through her/his tax code to all prescription/OTC 
drugs managed from October 2012 to March 2013, generating a 
personal pharmacologic profile. Data on age, sex, and comorbidity 
were collected in the beginning of the study. DDIs were identified and 
classified according to Mario Negri Institute definition in 3 severity 
groups: low (no suspension or change in therapy required), moderate 
(change in treatment, additional therapy or hospitalization required), 
and high (potentially fatal).
Results: A total of 369 patients (58.3% women) were included. 
About 30% shown 1 comorbidity and 11.8% 2 or more. 
Cardiovascular diseases (22.7%) represented the most frequent 
comorbidity, followed by musculoskeletal pathology (13.6%), dia-
betes (8.6%), cancer (5.1%), and depression (4.8%). The Charlson 
Comorbidity Index was 0 in 65.2%, 1 in 25.7%, 2 in 7.0% and 3 to 
4 in 2.1%. A total of 67 patients (mean age, 72 [12] years; 52.2% 
women) had at least 1 DDI. About 50% (N = 33) had up to 2 DDIs, 
25% from 3 to 7 DDIs and 25% ≥ 8 (from 9–74 DDIs per person). 
A total of 501 DDIs were identified: the severity was low in 35.5%, 
moderate in 59.7% and high in 4.8%. The top 10 drugs involved in 
DDI were: acetylsalicylic acid (ASA), hydrochlorothiazide, ibupro-
fen, diclofenac, digoxin, nebivolol, pantoprazole, ramipril, furosem-
ide, and nimesulide. DDIs occured more frequently with ASA and 
hydrochlorothiazide (6.2%), hydrochlorothiazide and pantoprazole 
(4.6%), ASA and ibuprofen (3.4%), ASA and nebivolol (3.4%), and 
ASA and nitroglycerin (3.2%). About 50% of DDIs involving ASA, 
hydrochlorothiazide, and ibuprofen were of low severity and another 
50% of moderate severity. For diclofenac, low severity DDIs were 
27.6% and 72.4% moderate while for digoxin 75.7% were moder-
ate and 24.3% high.
Conclusion: ICT technologies are useful to timely identify DDIs of 
clinical relevance and the drugs most frequently involved.
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Introduction: Due to its high solubility and low permeability, nado-
lol, a nonselective β -blocker, is categorized as a class III drug in a 
Biopharmaceutics Classification System, and therefore nadolol may 
require active influx transporters to permeate gut wall mucosa during 
intestinal absorption. Members of the organic anion transporting 
polypeptide (OATP) family such as OATP1A2 and OATP2B1 have 
previously been reported to be involved in intestinal absorption of 
several drugs. However, the molecular mechanism of nadolol uptake 
into enterocytes still remains unknown.
Patients (or Materials) and Methods: Human embryonic kidney 
(HEK) 293 cell lines stably expressing OATP1A2 or OATP2B1 were 
used to investigate whether nadolol is a substrate for these trans-
porters using [3H]nadolol. Epigallocatechin 3-gallate (EGCG), a 
flavonoid highly abundant in green tea, was used as an inhibitor of 
OATP1A2- and OATP2B1-mediated transport.
Results: No significant nadolol uptake was observed in 
OATP2B1-expressing cells. In contrast, the uptake of nadolol in 
OATP1A2-expressing cells was significantly greater than that in 
vector-transfected cells. OATP1A2-mediated nadolol uptake was 
saturable with Km and Vmax values of 84.3 (1.0) μ M and 332.8 
(125.5) pmol/min/mg protein, respectively. OATP1A2-mediated 
uptake of nadolol was inhibited in a concentration dependent man-
ner by EGCG with an IC50 value of 37.3 (5.9) μ M.
Conclusion: These data suggest that OATP1A2 is predominantly 
involved in the cellular uptake of nadolol, while the role of OATP2B1 
may be negligible. The inhibition of OATP1A2-mediated nadolol 
uptake might be involved in drug–drug and drug–food interactions 
with this β -blocker.
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Introduction: In cancer patients, coadministration of methotrexate 
(MTX) and proton pump inhibitors (PPIs) can cause a pharmacoki-
netic interaction for delayed elimination and a subsequent increase 
in blood MTX concentration. Human organic anion transporters 
hOAT1 (SLC22A6) and hOAT3 (SLC22A8) are responsible for renal 
tubular secretion of MTX. We hypothesized that they are involved 
in drug interaction of MTX with PPIs. The aim of this study was to 
evaluate the inhibitory potencies of PPIs on HEK-hOAT1 and HEK-
hOAT3 attempt to give an explanation to this possible drug–drug 
interaction between MTX and PPIs.
Patients (or Materials) and Methods: Uptake experiments were 
performed using HEK Flp-In 293, stably expressing human 
OAT1(SLC22A6) or OAT3 (SLC22A8), by using the Flp-In™ System 
recombinase (Invitrogen®). We analyzed whether the inhibitory 
potencies of omeprazole, lansoprazole, and pantoprazole on OAT-
mediated [3H] MTX uptake in vitro.
Results: MTX shown to be a high-affinity substrate for hOAT3 but 
not for hOAT1 ( hOAT3 Km = 21.17 [5.65] µM). All PPIs showed 
in vitro inhibition of hOAT transporters. For that purpose, PAH, and 
ES were selected for probing hOAT1 and hOAT3 activities. However, 
their IC50 values concerning hOAT1 were 10 to 30 times higher 
than the unbound plasma concentrations of the PPIs. Conducted in 
parallel [3H]MTX uptake into HEK hOAT3 cells was inhibited by all 
PPIs in a concentration-dependent manner omeprazole, lansoprazole, 
and pantoprazole inhibit hOAT3, their IC50 were in the range of the 
therapeutic levels of the IPPs (0.91–8.06 µM).
Conclusion: PPIs significantly affect transport of MTX mediated by 
hOAT3, but this interaction cannot be explained by the inhibitory 
effects of PPIs on renal hOAT1. These in vitro results demonstrate 
that alterations of uptake transporters of MTX function by IPPs 
drugs have to be considered as potential mechanisms underlying 
drug–drug interactions between MTX-IPPs.
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Introduction: Cytochrome P450 3A (CYP3A) is the major enzyme 
metabolizing drugs and xenobiotics in humans. The present study 
aimed to quantitate the extent of in vivo inhibition and induction 
effects of ritonavir, ketoconazole, and rifampin on the intestinal and 
hepatic activity of CYP3A in adult healthy Asians.
Patients (or Materials) and Methods: Fifteen healthy male or female 
Asian adults completed this open-label, single-center, sequential, par-
tial crossover study. Subjects underwent 4 periods of treatments: 
baseline (reference) period; period 1, either ketoconazole 200 mg or 
ritonavir 100 mg twice daily given for 3 days; period 2, either ritona-
vir or ketoconazole given for 3 days (periods 1 and 2 in a randomized 
crossover design); period 3, rifampin 600 mg given nightly for 2 
weeks. At the end of each period, each subject was administered with 
a single intravenous (IV) midazolam 0.75 mg, given in the fasting 
state, and a single oral 1.5-mg dose of midazolam 4 hours later. Serial 
blood samples were taken from the subjects at predose and at various 
time points for up to 12 hours after IV administration of midazolam. 
Concentrations of midazolam were measured using a validated LC/
MS-MS approach. The hepatic midazolam clearance after IV dosing 
was directly modeled in NONMEM and was estimated separately 
for the reference and the test periods. The intestinal midazolam avail-
ability was calculated by dividing oral midazolam availability with 
hepatic midazolam availability. Formal interaction was excluded if 
the 90% CI for the ritonavir, ketoconazole, or rifampin over reference 
ratios for phenotyping metrics (hepatic midazolam clearance and 
intestinal midazolam availability) was within a 0.80 to 1.25 range.
Results: Ritonavir reduced hepatic and intestinal CYP3A activity to 
0.68-fold (90% CI, 0.61–0.73) and to 0.36-fold (0.28–0.52), respec-
tively. Ketoconazole reduced hepatic and intestinal CYP3A activity 
to 0.75-fold (90% CI, 0.69–0.81) and 0.52-fold (0.39–0.83), respec-
tively. Rifampin increased hepatic and intestinal CYP3A activity by 
1.22-fold (90% CI, 1.02–1.42) and 1.41-fold (1.04–2.19), respec-
tively. There was a statistically significant and clinically relevant 
inhibition of the intestinal CYP3A activity due to chronic treatment 
with ritonavir.
Conclusion: Ritonavir treatment resulted in a clinically significant 
reduction in the net intestinal CYP3A activity. Extent of CYP3A 
inhibition produced by ketoconazole was smaller relative to ritonavir, 
especially at the intestinal level.
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Introduction: Estimation of prescription of warfarin (W) taking into 
account its interaction with other medicines in patients with coronary 
heart disease in clinical conditions.
Patients (or Materials) and Methods: The design of the research is 
retrospective. To estimate the level of polypharmacy and to analyze 
the interaction of W with other medicines medical documents of 
61 patients with coronary heart disease have been analyzed. The 
effects of interaction of medicines were estimated according to BNF 
(British National Formulary) in March 2013. Estimation of the level 
of polypharmacy was considered according to the following 3 groups: 
1, those who received 1 to 5 medicines. This shows rational use of 
medicines. 2, those who received 6 to 10 medicines; 3, those who 
received 11 to 15 medicines. The most clinically significant combina-
tions of medicines have been analyzed.
Results: It has been established that in total 61 patients received 
709 medicines. The medicine load for 1 patient was 11.6 medicines; 
77% of the patients received from 11 to 15 medicines, 23% of the 
patients received from 6 to 10 medicines. The research did not reveal 
any patients who received ≤5 medicines. The results testified to a high 
level of polypharmacy. The next stage is the study of combinations of 
W and medicines presenting significant risk in terms of clinical safety. 
W was given in combination with the following medicines: heparin 
– 16% of patients; acetylsalicylic acid (AS acid) – 28% of patients; 
omeprazole – 21%; diclofenac – 13%; ciprofloxacin – 11%; metro-
nidazole – 5%. It has been proved that the combinations of W and 
heparin, AS acid, and omeprazole are inadmissible, because they are 
life-threatening due to hemorrhage complications. Other unfavorable 
combinations of W have been revealed. They are: W + AS acid + 
omeprazole – 10% of patients; W + AS acid + ciprofloxacin – 4%; 
W + AS acid + diclofenac – 14%. These combinations significantly 
increase the risk of gastrointestinal bleeding.
Conclusion: The real clinical practice in hospitals revealed irra-
tional prescription of medicines. The research has registered a high 
level of polypharmacy and dangerous combinations of W with 
other medicines. It has been proved that before prescribing treat-
ment with W it is necessary to consider pharmacology genetics 
options, which are widely used worldwide. This kind of research 
has not been done in Kyrgyzstan. This determines the importance 
of personalized approach to pharmacologic therapy of W. This 
